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Randomized clinical trial comparing multiple stab incision phlebec-
tomy and transilluminated powered phlebectomy for varicose veins
Chetter IC, Mylankal KJ, Hughes H, et al. Br J Surg 2006;93:169-74.
Conclusion: Transilluminated power phlebectomy (TIPP) compared
with multiple stab incision phlebectomy (MSIP) results in fewer surgical
incisions but has reduced early postoperative quality of life, with more
extensive bruising and more prolongation of postoperative pain.
Summary: This was a randomized clinical trial at a university teaching
hospital in Australia. Patients who were to undergo surgery for varicose veins
were randomized to receive either TIPP or MSIP for treatment of the
varicosities. For both groups, analysis consisted of operative times, number
of incisions, and postoperative outcome. A quality-of-life analysis was con-
ducted at 1 and 6 weeks after surgery using disease-specific (Aberdeen
varicose vein questionnaire) and generic (Short Form 36 and EuroQual 5D)
measures as well as the domain-specific Burford Pain Scale. TheMSIP arm of
the trial had 33 patients, and the TIPP arm had 29 patients. All patients had
complicated or symptomatic varicose veins. In theMSIP group, 29 of the 33
patients were CEAP class II, and 27 of 29 patients in the TIPP group were
CEAP class II.
Mean duration of surgery was 48 minutes (range, 41 to 63 minutes) in
the MSIP patients and 50 minutes (range, 40 to 60 minutes) in the TIPP
group (P  .717). A significantly lower number of phlebectomy incisions
were used in the TIPP group (mean, 5; range, 3 to 7), than the MISP group
(mean, 20; range, 11 to 25) (P .001). At 1 and 6 weeks, skin bruising was
significantly higher in the TIPP group (P .01), and the Burford Pain Scale
at 6 weeks was also significantly higher in the TIPP group (P  .019). At 1
week after surgery, both groups had significant deterioration on the quality-
of-life outcomes domains of physical function, role play, and social function
of the SF36. The magnitude of deterioration was greater after TIPP. At 6
weeks, patients who had TIPP had no significant change in any SF36
quality-of-life domain compared with pretreatment values. Patients treated
with MSIP at 6 weeks showed significant improvements in role play and in
physical and bodily pain.
Comment: In this randomized trial of transilluminated power phlebec-
tomy vs standard multiple stab incisions for varicose vein treatment, the only
advantage of the transilluminated power phlebectomy was a decreased
number of incisions. Surprisingly, there was no difference in operative time.
If patient recovery is the issue, it therefore appears that standard multiple
incisions provide a better outcome. If the patient is interested in fewer
incisions for cosmetic concerns, transilluminated power phlebectomy will
provide this but at the expense of a more prolonged recovery from the initial
procedure.
Slow-flow phenomenon during carotid artery intervention with em-
bolic protection devices
Casserly IP, Abou-Chebal A, Fathi RB, et al. J Am Coll Cardiol 2005;46:
1466-72.
Conclusion: Carotid interventions with emboli protection devices are
frequently associated with slow-flow phenomenon. Slow-flow phenomenon
is associated with an increased risk of periprocedural stroke.
Summary: Slow flow during carotid angioplasty and stenting is de-
scribed as occurring when there is angiographic evidence of significant
reduction of antegrade flow in the internal carotid artery proximal to the
embolic protection device. The mechanism of slow flow during carotid
percutaneous procedures is unknown, but it is hypothesized that debris may
result in blockage of the filter, impeding antegrade flow. The authors sought
to examine predictors of slow flow during carotid artery angioplasty and
stenting with embolic protection devices.
Data were derived from a single-center carotid intervention registry
that was maintained prospectively. Patients with normal flow during carotid
intervention and those with slow flow were compared with respect to clinical
procedure, lesion characteristics, and 30-day incidence of death and stroke.
There were 453 carotid interventions with embolic protection devices
performed in 414 patients. Slow flow was observed in 42 patients (10.1%)
and most commonly occurred after stent balloon dilatation (71.4%). Multi-
variant logistic regression analysis was used to identify predictors of slow
flow. They included a recent history (6 months) of transient ischemic
attack or stroke (odds ratio, 2.8; 95% confidence interval, 1.4 to 5.6, P 
.004). In addition, increased stent diameter and increased patient age were
also associated with slow flow. Among patients with slow flow, 30-day
incidence of stroke or death was 9.5% compared with 2.9% in patients with
normal flow (P  .03).
Comment: It makes sense that if enough debris is trapped in the
cerebral protection device, flow will be reduced through the ipsilateral
internal carotid artery. However, it may be the increased debris in the
protection device is also a marker of increased embolization at the time the
lesion is initially crossed. The strokes therefore could be embolic hemody-
namic in origin.
Bypass versus angioplasty in severe ischaemia of the leg (BASIL):
Multicentre, randomised, controlled trial
Adam DJ, Beard JD, Cleveland T, et al; BASIL Trial Participants. Lancet
2005;366:1925-34.
Conclusion: Patients with critical limb ischemia secondary to infrain-
guinal occlusive disease and who are suitable for either angioplasty or surgery
have similar short-term results with regard to amputation-free survival with
either a bypass surgery-first strategy or a balloon angioplasty-first strategy.
Summary: The BASIL trial was designed to compare a surgery-first
strategy vs balloon angioplasty-first strategy in patients with rest pain,
ulceration, or gangrene of the lower extremity. There were 27 hospitals in
the United Kingdom that participated in the study. Investigators randomly
assigned 452 patients with severe limb ischemia secondary to infrainguinal
disease to receive an angioplasty-first strategy (n  224) or a surgery-first
strategy (n  228). Analysis was by intention to treat, and the primary end
point was amputation-free survival. Patient follow-up ended when the
patient reached an end point of either amputation of the trial leg above the
ankle or died. Secondary outcomes were all-cause mortality, 30-day mor-
bidity and mortality, health-related quality of life, use of hospital resources,
and need for reinterventions. Patients had to be considered suitable for
randomization by both consultant vascular surgeons and interventional
radiologists.
The authors also audited patients from the six top recruiting centers
who presented with critical limb ischemia and were thought to be suitable
for randomization. After survival curves were examined, a post hoc analysis
was done comparing risk of end points occurring between randomization
and 2 years and end points occurring 2 years.
During the 6-month audit, 585 consecutive patients with critical limb
ischemia presented to the top six recruiting centers, and 129 (29%) needed
suprainguinal revascularization. Of the remaining patients with critical limb
ischemia, 220 (48%) were treated without revascularization; therefore, 52%
of the patients (n  236) presenting with critical limb ischemia underwent
revascularization. Of these 236 potentially eligible patients, 70 (29%) were
regarded as suitable for randomization into the trial, but 22 (31%) refused
trial entry, thus leaving 48 for randomization. The audit results thus suggest
10% of the patients presenting with critical limb ischemia would be
randomized into the BASIL trial.
Overall, 195 (86%) of 228 patients assigned to bypass surgery and 216
(96%) of 224 assigned to balloon angioplasty underwent attempts at their
allocated intervention. At the end of the follow-up, 55% of the patients (n
248) were alive without amputation of the trial leg. Eight percent of patients
(n  38) were alive with amputation, 8% (n  36) were dead after
amputation, and 130 patients were dead without amputation (29%).
The immediate technical failure rate for the patients assigned to surgery
was 3% (5 of 195). The immediate technical failure rate of the patients
assigned to angioplasty was 20% (n 43). The difference in 30-daymortality
between the two treatment strategies was not significant. Surgery was
associated with a significantly higher early morbidity rate (53%) than angio-
plasty (41%). Morbidity events were primarily wound, infectious, and car-
diovascular complications. No difference was noted in health related quality
of life between the two treatment strategies. First year hospital costs were
higher with a surgery-first strategy. At 6 months, the two strategies did not
differ with respect to amputation-free survival (adjusted hazard ratio, 0.73,
94% confidence interval, 0.49 to 1.07). After 2 years, surgery seemed to be
associated with a significantly reduced risk of future amputations, death, or
both.
Comment: The article raises several interesting points. It is very
difficult to recruit for trials of critical limb ischemic patients. The audit data
suggests 10% of the patients screened for the trial would be eligible for
randomization. In the short-term, results are similar in patients who are
suitable both for angioplasty or surgery. Morbidity and expense are greater
with surgery, but long-term amputation-free survival may be improved by a
surgery-first strategy.
Overall, the trial results would appear to be as expected.With respect to
the lower extremities, there is a constant theme with respect to angioplasty
and surgery. If short-term results are what matter, and the patient can be
treated with either angioplasty or surgery, angioplasty is the likely preferred
strategy. However, in patients with suitable anatomy and a reasonable life
expectancy, surgery may be a better alternative, accepting increased short-
term morbidity as a price for greater long-term durability.
Ethnicity and peripheral arterial disease: The San Diego Population
Study
Criqui MH, Vargas V, Denenberg JO, et al. Circulation 2005;112:2703-7.
Conclusion: Black ethnicity is a strong risk factor for peripheral arterial
disease (PAD) independent of diabetes, hypertension, and body mass index.
Summary: There appears to be excess PAD in black patients than in
non-Hispanic whites (NHWs). Little information is available for Asians and
Hispanics. The San Diego Population Study sought to assess PAD preva-
lence rates in a defined population that included four ethnic groups: NHWs,
blacks, Hispanics, and Asians. Patients in the study were randomly selected
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